Amanote Research
Register
Sign In
Orphan Designation: Eculizumab, Treatment of Paroxysmal Nocturnal Haemoglobinuria
Case Medical Research
doi 10.31525/cmr-1b7df2b
Full Text
Open PDF
Abstract
Available in
full text
Date
August 30, 2019
Authors
Unknown
Publisher
Case Journals
Related search
Paroxysmal Nocturnal Haemoglobinuria
The Pathophysiology of Paroxysmal Nocturnal Hemoglobinuria and Treatment With Eculizumab
Therapeutics and Clinical Risk Management
Recurrent Bowel Infarction in Paroxysmal Nocturnal Haemoglobinuria
Journal of the Royal Society of Medicine
Medicine
Neisseria Elongata Infection Associated With Complement Inhibition During Treatment of Paroxysmal Nocturnal Haemoglobinuria
British Journal of Haematology
Hematology
Recurrent Cerebral Ischaemic Events in the Setting of Paroxysmal Nocturnal Haemoglobinuria
BMJ Case Reports
Medicine
Orphan Designation: Brincidofovir, Treatment of Smallpox
Case Medical Research
Assessment of Human Antihuman Antibodies to Eculizumab After Long-Term Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria
American Journal of Hematology
Hematology
Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient With Paroxysmal Nocturnal Hemoglobinuria
Case Reports in Hematology
Paroxysmal Nocturnal Haemoglobinuria-Like Defect in Red Cells in Chronic Lymphatic Leukaemia.
BMJ
